Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Total Non-Current Liabilities (2016 - 2025)

IGC Pharma (IGC) has disclosed Total Non-Current Liabilities for 15 consecutive years, with $137000.0 as the latest value for Q3 2025.

  • Quarterly Total Non-Current Liabilities fell 27.89% to $137000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $137000.0 through Sep 2025, down 27.89% year-over-year, with the annual reading at $160000.0 for FY2025, 33.61% down from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $137000.0 at IGC Pharma, down from $140000.0 in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $696000.0 in Q1 2021, with the low at $137000.0 in Q3 2025.
  • Average Total Non-Current Liabilities over 5 years is $353842.1, with a median of $340000.0 recorded in 2023.
  • Peak annual rise in Total Non-Current Liabilities hit 38.92% in 2021, while the deepest fall reached 46.73% in 2021.
  • Over 5 years, Total Non-Current Liabilities stood at $534000.0 in 2021, then decreased by 25.66% to $397000.0 in 2022, then plummeted by 31.99% to $270000.0 in 2023, then plummeted by 40.0% to $162000.0 in 2024, then dropped by 15.43% to $137000.0 in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $137000.0, $140000.0, and $160000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.